



FINAL – FOR IMMEDIATE RELEASE

Millendo Therapeutics Expands Management Team with Addition of Two Vice Presidents

Company Adds Senior Expertise with Appointments in Commercial Strategy and Preclinical Research and Development

ANN ARBOR, Mich., Apr. 14, 2016 – [Millendo Therapeutics, Inc.](#), a company developing novel therapies for endocrine diseases caused by hormone dysregulation, today announced the appointment of Thomas Hoover as Vice President, Commercial Strategy and Andrew G. Spencer, Ph.D. as Vice President, Preclinical Research and Development. Mr. Hoover will be responsible for development and implementation of the commercial strategy for MLE4901 and ATR-101 and joins Millendo from Sunovion Pharmaceuticals. Dr. Spencer will be responsible for the Company's preclinical operations including toxicology, pharmacology, and PK/ADME studies and joins Millendo from Ardelyx, Inc.

"Tom and Andy are experienced, driven individuals who will be valuable additions to our management team at a critical stage in the Company's development," said Julia C. Owens, Ph.D., President and Chief Executive Officer of Millendo. "Together, their contributions will be central to the advancement of our mission to improve the quality of life for patients with endocrine diseases who have limited or no approved treatment options."

Mr. Hoover most recently served as Vice President, New Products Planning and Corporate Development at Sunovion Pharmaceuticals, where he was responsible for product strategy, portfolio management and business development. Prior to Sunovion, Mr. Hoover was a Senior Director in the Global Commercial Strategy group at GlaxoSmithKline, where he provided commercial input into R&D decision making. Before starting his pharmaceutical career, Mr. Hoover spent four years at The Boston Consulting Group. Mr. Hoover earned his MBA from the Kenan-Flagler Business School at the University of North Carolina and a B.A. in economics from Harvard College.

"It is an honor to have the opportunity to join Millendo at such a transformative time in the Company's growth," said Mr. Hoover. "I am eager to lead the development and implementation of commercial strategy for two therapeutic candidates with great potential to make a difference for patients - MLE4901, a first-in-class oral drug candidate for the treatment of polycystic ovary syndrome, and ATR-101, a novel, oral drug candidate indicated for the treatment of adrenocortical carcinoma, congenital adrenal hyperplasia, and Cushing's syndrome."

Dr. Spencer most recently served as Vice President, Pharmacology/DMPK at Ardelyx, Inc., where he made extensive contributions to the discovery and development of tenapanor and served as head of alliance management during partnerships with Sanofi and AstraZeneca. Prior to his time at Ardelyx, Dr. Spencer made significant early contributions to emerging treatments for celiac disease as a scientist at the Celiac Sprue Research Foundation and Alvine Pharmaceuticals. Previously, he held scientist positions at Mirus Bio (now part of Arrowhead Research), where he worked on early drug discovery applications of siRNAs, and at the humanized monoclonal antibody innovator PDL BioPharma. Dr. Spencer earned his Ph.D. in biochemistry from Michigan State University and a B.S. in chemistry from Hope College.

"I am thrilled to join Millendo's highly experienced management team," said Dr. Spencer. "I look forward to utilizing my experience in preclinical drug development to lead advancement of the Company's preclinical programs as we look to build a significant pipeline around endocrine diseases."

About Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing a portfolio of disease-modifying treatments for endocrine diseases caused by hormone dysregulation. Our product candidates seek to improve the quality of life for patients with orphan and specialty diseases with limited or no approved treatment options. Our clinical programs are designed to address:

- Polycystic Ovary Syndrome (PCOS) – the most common endocrine disease in women
- Adrenocortical Carcinoma (ACC) – a rare endocrine malignancy of the adrenal cortex
- Congenital Adrenal Hyperplasia (CAH) – a recessive genetic defect of cortisol synthesis
- Endogenous Cushing's Syndrome (CS) – a condition resulting from chronic cortisol excess

Our experienced team is committed to bringing these first-in-class therapies to market.

www.millendo.com

###

Media Contact:

Blair McCarthy Atkinson
MacDougall Biomedical Communications
Main: +1 781 235 3060
Direct: +1 812 454 6257
batkinson@macbiocom.com